RT @DimitriEynikel: 2) today the @EU_Commission proposed a unitary SPC which prolong patents in EU by up to 5 years. Our own research has…
2) today the @EU_Commission proposed a unitary SPC which prolong patents in EU by up to 5 years. Our own research has shown the negative impact of SPC on access to medicines in Europe. They are costly, not needed & can cut people of treatment. https:/
Companies don't need to proof the patent term is too short to recoup R&D investments to get an SPC. My own research showed that pharma companies don't need SPCs: - After 4 years they recoup R&D -after this patent term still >10 years💰🏖️ Why nee
RT @DimitriEynikel: 1) Proud to share our peer reviewed article: Supplementary protection certificates and their impact on #access2medicine…
De negatieve effecten van patentverlengingen zijn evident, hogere prijzen. Ze zijn ook in Europa controversieel, laat staan daarbuiten. Hier is mijn onderzoek👇: Ze zijn geldverspilling en kunnen ultiem leiden tot het lijden en de dood van patiënten. 2/ htt
RT @DimitriEynikel: 1) Proud to share our peer reviewed article: Supplementary protection certificates and their impact on #access2medicine…
Ook bij ons is het verhaal van tenofovir interessant. Zo vond Gilead manieren om het patent te blijven verlengen. In combinatie met emtricitabine, prijs voor een doosje 30 stuks in 2018: gepatenteerd in België 380 euro niet-gepatenteerd in NL 48 euro 6/ h
And, to those who argue that SPCs are needed for pharma to recoup their Research & Development investments, our peer-reviewed analysis found this not to be true🤔. https://t.co/yXqgmW9okx
4. Pharma companies claim SPCs are needed bc 20 years patents are not long enough to recoup R&D investments. Our research showed companies recouped investments in less than 4 years. After that 10 more years of patent time + extra time under SPCs! https
2. SPC's prolong monopolies up to 5 years on top of the standard 20 year patent term, so higher prices for longer time. Our analysis shows the SPC system are unnecessary cost for society, which may cause avoidable suffering or deaths. https://t.co/NU1bF
Great panel #A2MDialogues today hosted by @YNatsis @EPHA_EU on #intellectualproperty and access to medicines. For more info on SPCs and access to medicines, our article to add to your reading list 👇 https://t.co/NU1bFycnrV
RT @South_Centre: Extending #PatentTerm beyond the #TRIPS standard delayed competition & kept high prices for #HepatitisC (sofosbuvir) & #C…
RT @South_Centre: Extending #PatentTerm beyond the #TRIPS standard delayed competition & kept high prices for #HepatitisC (sofosbuvir) & #C…
RT @DimitriEynikel: 1) Proud to share our peer reviewed article: Supplementary protection certificates and their impact on #access2medicine…
RT @South_Centre: Extending #PatentTerm beyond the #TRIPS standard delayed competition & kept high prices for #HepatitisC (sofosbuvir) & #C…
RT @South_Centre: Extending #PatentTerm beyond the #TRIPS standard delayed competition & kept high prices for #HepatitisC (sofosbuvir) & #C…
RT @South_Centre: Extending #PatentTerm beyond the #TRIPS standard delayed competition & kept high prices for #HepatitisC (sofosbuvir) & #C…
RT @South_Centre: Extending #PatentTerm beyond the #TRIPS standard delayed competition & kept high prices for #HepatitisC (sofosbuvir) & #C…
RT @DimitriEynikel: 1) Proud to share our peer reviewed article: Supplementary protection certificates and their impact on #access2medicine…
@ojwouters @JAMA_current @martinmckee @jeroen_luyten Interesting study & it relates to our own study on a pharma companies' propagated presumption that the 20 years patent doesn't suffice to earn back R&D investments, hence the need for patent term
RT @EllaWeggen: Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastu…
Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib https://t.co/6OrAmBc9FL
RT @MSFsci: Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzuma…
RT @MSFsci: Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzuma…
RT @MSFsci: Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzuma…
RT @MSFsci: Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzuma…
Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib, review by @MSF in Journal of Pharmaceutical Policy and Practice: https://t.co/q26Rg43EOw @MSF_access
RT @GiraudSylvain: "The addition of SPC exclusivity has heavily delayed competition and maintained high medicines prices in European countr…
RT @GiraudSylvain: "The addition of SPC exclusivity has heavily delayed competition and maintained high medicines prices in European countr…
RT @GiraudSylvain: Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, tra…
RT @GiraudSylvain: "The addition of SPC exclusivity has heavily delayed competition and maintained high medicines prices in European countr…
RT @MSFsci: Supplementary protection certificates & their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab…
RT @MSFsci: Supplementary protection certificates & their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab…
Supplementary protection certificates & their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib, Review by @MSF in Journal of Pharmaceutical Policy & Practice: https://t.co/qolJFfiPv6 @MSF_access @BioMedC
RT @DimitriEynikel: 1) Proud to share our peer reviewed article: Supplementary protection certificates and their impact on #access2medicine…
RT @DimitriEynikel: 1) Proud to share our peer reviewed article: Supplementary protection certificates and their impact on #access2medicine…
RT @DimitriEynikel: 1) Proud to share our peer reviewed article: Supplementary protection certificates and their impact on #access2medicine…
RT @DimitriEynikel: 1) Proud to share our peer reviewed article: Supplementary protection certificates and their impact on #access2medicine…
RT @DimitriEynikel: 1) Proud to share our peer reviewed article: Supplementary protection certificates and their impact on #access2medicine…
#PublicHealth #Europe Supplementary protection certificates and their impact on #access2meds: case studies of sofosbuvir, trastuzumab and imatinib https://t.co/2jqutgzVlS Yuanqiong Hu, @DimitriEynikel, @PascaleBoulet, @gaellekrikorian @editorjoppp v @Ele_V
1) Proud to share our peer reviewed article: Supplementary protection certificates and their impact on #access2medicines in Europe. @editorjoppp @PascaleBoulet @gaellekrikorian #intellectualproperty #innovation #cancer #hepc Thread https://t.co/NU1bFycnrV
RT @editorjoppp: Supplementary protection certificates and their impact on #access to #medicines in #Europe: case studies of sofosbuvir, tr…
#European policies, right to #health and #universalhealthcoverage: "Ultimately, the granting of such extended exclusive private rights on #medicines may result in unnecessary suffering and be a factor in the erosion of #access to medicines for all" @editor
Supplementary protection certificates and their impact on #access to #medicines in #Europe: case studies of sofosbuvir, trastuzumab and imatinib https://t.co/2v8T3wx9C1